EUVIMEDObjevte EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review

Huriye Seyma Kafa iD, Sabina Chaudhary Hauge iD, Ditte Hansen

Basic & Clinical Pharmacology & Toxicology · 2026

DOI: 10.1111/bcpt.70293 ↗

At a glance

Systematische Übersicht in Basic & Clinical Pharmacology & Toxicology, 2026. Written by Huriye Seyma Kafa and 2 co-authors. Institution: Department of Nephrology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark. Major MEDLINE topics: Renal Insufficiency, Chronic, Teriparatide, Bone Density Conservation Agents, Osteoporosis. 33 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Augustinus Foundation, Augustinus Fonden.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Chronic kidney disease (CKD) associated osteoporosis leads to an increased risk of bone fracture in patients with CKD. Evidence on the efficacy and safety of anti‐osteoporotic medications is limited for this group. This systematic review aimed to examine the efficacy and safety of anabolic parathyroid hormone (PTH) treatment in patients with CKD Stages 4–5D.

Methods

MEDLINE, EMBASE and ClinicalTrials.gov were searched systematically for randomized controlled trials (RCTs) investigating teriparatide, natpara, or abaloparatide in adult patients with CKD Stages 4–5D, including kidney transplant recipients. The primary outcome was the change in bone mineral density (BMD) during follow‐up measured at the lumbar spine (LS), femoral neck (FN) and total hip (TH). The secondary outcomes included bone turnover markers, fractures, histomorphometric results from bone biopsies and adverse events (AEs).

Results

Two RCTs were included. A subgroup analysis of patients with CKD Stage 4 ( n = 5) showed that teriparatide improved BMD at the LS and FN. Another trial ( n = 61) in CKD Stage 5D showed significant BMD improvement at the TH compared to the control group. AEs were observed with higher frequency in the teriparatide‐treated group.

Conclusion

Treatment with teriparatide seems to improve BMD in patients with CKD Stages 4–5D, but evidence on efficacy and safety is limited. Trial Registration PROSPERO: CRD42024527086

Subjects

MeSH terms (MEDLINE)

Renal Insufficiency, ChronicTeriparatideBone Density Conservation AgentsOsteoporosisAnabolic AgentsHumansBone DensityRandomized Controlled Trials as TopicParathyroid HormoneParathyroid Hormone-Related ProteinTreatment Outcome

Author keywords

abaloparatidebone mineral densitychronic kidney diseasenatpararandomized controlled trialteriparatide

Substances

TeriparatideBone Density Conservation AgentsParathyroid HormoneAnabolic AgentsParathyroid Hormone-Related Protein

Authors and institutions

  • Department of Nephrology, Copenhagen University Hospital - Herlev and Gentofte Hospital, Herlev, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

ORCID profiles: Huriye Seyma Kafa, Sabina Chaudhary Hauge

Funding

  • Augustinus Foundation
  • Augustinus Fonden

Cite

APA

Kafa, H. S., Hauge, S. C., & Hansen, D. (2026). Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70293

Vancouver

Kafa HS, Hauge SC, Hansen D. Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70293

BibTeX
@article{Kafa2026,
  author = {Kafa, Huriye Seyma and Hauge, Sabina Chaudhary and Hansen, Ditte},
  title = {Bone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2026},
  doi = {10.1111/bcpt.70293}
}
Start for free →